| Balance Sheet of GlaxoSmithKline Pharmaceuticals (in Rs. Cr.) |
Mar 25 |
Mar 24 |
Mar 23 |
Mar 22 |
Mar 21 |
|
| |
12 mths |
12 mths |
12 mths |
12 mths |
12 mths |
|
| EQUITIES AND LIABILITIES |
|
|
|
|
|
|
| SHAREHOLDER'S FUNDS |
|
|
|
|
|
|
| Equity Share Capital |
169.41 |
169.41 |
169.41 |
169.41 |
169.41 |
|
| Total Share Capital |
169.41 |
169.41 |
169.41 |
169.41 |
169.41 |
|
| Reserves and Surplus |
1,779.82 |
1,614.68 |
1,585.27 |
2,508.21 |
1,327.71 |
|
| Total Reserves and Surplus |
1,779.82 |
1,614.68 |
1,585.27 |
2,508.21 |
1,327.71 |
|
| Total Shareholders Funds |
1,949.23 |
1,784.09 |
1,753.00 |
2,677.62 |
1,497.12 |
|
| NON-CURRENT LIABILITIES |
|
|
|
|
|
|
| Long Term Borrowings |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Deferred Tax Liabilities [Net] |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Other Long Term Liabilities |
2.49 |
6.55 |
4.13 |
9.67 |
22.29 |
|
| Long Term Provisions |
248.40 |
246.21 |
253.55 |
260.96 |
258.25 |
|
| Total Non-Current Liabilities |
250.89 |
252.76 |
257.67 |
270.63 |
280.54 |
|
| CURRENT LIABILITIES |
|
|
|
|
|
|
| Short Term Borrowings |
0.00 |
0.00 |
0.00 |
0.00 |
0.02 |
|
| Trade Payables |
704.01 |
613.25 |
418.56 |
546.63 |
447.99 |
|
| Other Current Liabilities |
780.40 |
504.18 |
480.67 |
799.75 |
596.79 |
|
| Short Term Provisions |
416.41 |
393.52 |
417.79 |
327.98 |
274.62 |
|
| Total Current Liabilities |
1,900.81 |
1,510.95 |
1,317.03 |
1,674.35 |
1,319.42 |
|
| Total Capital And Liabilities |
4,100.93 |
3,547.80 |
3,327.70 |
4,622.60 |
3,097.08 |
|
| ASSETS |
|
|
|
|
|
|
| NON-CURRENT ASSETS |
|
|
|
|
|
|
| Tangible Assets |
269.54 |
297.70 |
294.81 |
294.95 |
342.20 |
|
| Intangible Assets |
13.33 |
23.55 |
34.09 |
34.50 |
43.36 |
|
| Capital Work-In-Progress |
14.32 |
13.93 |
20.31 |
30.50 |
13.21 |
|
| Other Assets |
0.76 |
0.00 |
1.04 |
1.18 |
1.33 |
|
| Fixed Assets |
297.95 |
335.18 |
350.25 |
361.13 |
400.10 |
|
| Non-Current Investments |
24.49 |
24.49 |
24.49 |
24.49 |
24.49 |
|
| Deferred Tax Assets [Net] |
140.64 |
145.95 |
133.18 |
112.78 |
101.67 |
|
| Long Term Loans And Advances |
4.00 |
11.00 |
88.10 |
204.60 |
0.00 |
|
| Other Non-Current Assets |
250.30 |
56.87 |
264.96 |
248.88 |
399.49 |
|
| Total Non-Current Assets |
717.38 |
573.49 |
860.98 |
951.89 |
925.75 |
|
| CURRENT ASSETS |
|
|
|
|
|
|
| Current Investments |
1,118.25 |
813.22 |
518.29 |
365.59 |
0.00 |
|
| Inventories |
463.17 |
514.30 |
437.70 |
512.71 |
523.34 |
|
| Trade Receivables |
292.55 |
222.06 |
192.38 |
205.24 |
215.60 |
|
| Cash And Cash Equivalents |
1,400.89 |
1,061.20 |
1,150.73 |
2,479.11 |
1,157.68 |
|
| Short Term Loans And Advances |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| OtherCurrentAssets |
108.70 |
363.53 |
167.62 |
108.05 |
274.71 |
|
| Total Current Assets |
3,383.55 |
2,974.31 |
2,466.72 |
3,670.71 |
2,171.33 |
|
| Total Assets |
4,100.93 |
3,547.80 |
3,327.70 |
4,622.60 |
3,097.08 |
|
| OTHER ADDITIONAL INFORMATION |
|
|
|
|
|
|
| CONTINGENT LIABILITIES, COMMITMENTS |
|
|
|
|
|
|
| Contingent Liabilities |
487.56 |
0.00 |
358.51 |
365.29 |
493.24 |
|
| CIF VALUE OF IMPORTS |
|
|
|
|
|
|
| Raw Materials |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Stores, Spares And Loose Tools |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Trade/Other Goods |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Capital Goods |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| EXPENDITURE IN FOREIGN EXCHANGE |
|
|
|
|
|
|
| Expenditure In Foreign Currency |
799.91 |
0.00 |
1,563.00 |
885.26 |
1,139.71 |
|
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS |
|
|
|
|
|
|
| Dividend Remittance In Foreign Currency |
-- |
-- |
-- |
-- |
-- |
|
| EARNINGS IN FOREIGN EXCHANGE |
|
|
|
|
|
|
| FOB Value Of Goods |
-- |
-- |
-- |
-- |
-- |
|
| Other Earnings |
167.68 |
-- |
162.17 |
52.78 |
27.80 |
|
| BONUS DETAILS |
|
|
|
|
|
|
| Bonus Equity Share Capital |
125.39 |
-- |
125.39 |
125.39 |
125.39 |
|
| NON-CURRENT INVESTMENTS |
|
|
|
|
|
|
| Non-Current Investments Quoted Market Value |
-- |
-- |
-- |
-- |
-- |
|
| Non-Current Investments Unquoted Book Value |
24.49 |
-- |
24.49 |
24.49 |
24.49 |
|
| CURRENT INVESTMENTS |
|
|
|
|
|
|
| Current Investments Quoted Market Value |
-- |
-- |
-- |
-- |
-- |
|
| Current Investments Unquoted Book Value |
-- |
-- |
-- |
-- |
-- |
|
Source : Dion Global Solutions Limited
